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Tuberculosis in HIV-infected children in Europe, Thailand and Brazil: paediatric TB:HIV EuroCOORD 53 
study 54 
 55 
SUMMARY  56 
Setting:  Centers participating in the Paediatric European Network for Treatment of AIDS (PENTA) 57 
including Thailand and Brazil. 58 
Objective:  To describe incidence, presentation, treatment and treatment outcomes of tuberculosis (TB) 59 
in human immunodeficiency virus (HIV) infected children.  60 
Design:  Observational study of TB diagnosed in HIV-infected children in 2011-2013.  61 
Results:  Of 4265 children aged <16 years, 127 (3%) were diagnosed with TB: 6 (5%) in Western Europe, 62 
80 (63%) in Eastern Europe, 27 (21%) in Thailand and 14 (11%) in Brazil, with estimated TB incidence 63 
rates of respectively 239, 982, 1633 and 2551 per 100,000 person-years (PY). The majority (94%) had 64 
acquired HIV perinatally. The median age at TB diagnosis was 6.8 years (interquartile range 3.0-11.5). 65 
Over half (52%) had advanced/severe World Health Organization stage immunodeficiency; 67 (53%) 66 
were not on antiretroviral therapy (ART) at TB diagnosis. Preventive anti-tuberculosis treatment was 67 
given to 23% (n=23) of 102 children diagnosed with HIV before TB.  Eleven children had unfavourable TB 68 
outcomes: 4 died, 5 did not complete treatment, 1 had recurrent TB and 1 had an unknown outcome. In 69 
univariable analysis, previous diagnosis of acquired immune-deficiency syndrome, not being virologically 70 
supressed on ART at TB diagnosis, and region (Brazil) were significantly associated with unfavourable TB 71 
outcomes.  72 
Conclusion:  Most TB cases were from countries with high TB prevalence. The majority (91%) had 73 
favourable outcomes. Universal ART and TB prophylaxis may reduce missed opportunities for TB 74 
prevention. 75 
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Tuberculosis in HIV-infected children in Europe, Thailand and Brazil: paediatric TB:HIV EuroCOORD 92 
study 93 
 94 
INTRODUCTION 95 
In 2014, there were an estimated 9.6 million new cases of tuberculosis (TB) globally, including 1 million 96 
children. TB is the leading cause of mortality and morbidity in people living with the human 97 
immunodeficiency virus (HIV), and in 2015 TB caused 55,000 deaths in HIV-infected children, comprising 98 
40% of all TB-related childhood deaths.1 The highest burden of coinfection occurs in sub-Saharan Africa, 99 
with 3-47% of HIV-infected children reported to have TB in different cohorts.2-5  100 
Although antiretroviral therapy (ART) substantially reduces TB incidence in HIV-infected children,2,4-7 it 101 
may not completely restore functional immune response against the disease and other environmental 102 
TB risk factors remain in this population. In the ART era TB incidence remains higher in HIV-infected 103 
children than in non-infected children or the general paediatric population, regardless of setting.3,5,8,9 TB 104 
diagnosis is difficult in children with HIV infection due to overlapping clinical presentations and frequent 105 
HIV-related respiratory comorbidities. Furthermore, confirmation of TB is challenging because of the 106 
paucibacillary nature of disease and difficulties in obtaining specimens in children; diagnosis is therefore 107 
often presumptive, complicating effective management.  108 
Successful anti-tuberculosis treatment (ATT) outcomes in HIV-infected children vary across settings, 109 
ranging from 69% to 88%.2,10-11 Concomitant ATT may compromise HIV virological control due to drug 110 
interactions between rifamycins and some antiretrovirals, leading to longer time to viral load (VL) 111 
suppression and higher resistance mutation rates.12-14 112 
Data on TB in children living with HIV in high- and middle-income settings in the combination ART era 113 
are scarce. Our aim was to describe incidence, clinical presentation, treatment and treatment outcomes 114 
of TB in HIV-infected children in the cohorts and clinical sites collaborating in the Paediatric European 115 
Network for Treatment of AIDS (PENTA), including Thailand and Brazil.  116 
  117 
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MATERIALS AND METHODS 118 
The Paediatric TB-HIV Observational Study was established as part of EuroCoord, an EU funded network 119 
of excellence on enhancing clinical and epidemiological HIV research in Europe through cohort 120 
collaboration (http://www.eurocoord.net). Of 28 multicentre cohorts and clinical sites approached, 15 121 
cohorts/sites collaborating within PENTA (http://penta-id.org/hiv.html) participated (Fig 1). HIV-infected 122 
children (aged <16 years) diagnosed with TB within a 3-year period, from 1 January 2011 to 31 123 
December 2013, at the time of TB diagnosis were included. Patients were followed-up for two years 124 
from TB diagnosis.  125 
Anonymised patient data were collected on standardised forms by collaborating physicians. Variables 126 
included sociodemographics, history of TB contact, growth measurements, HIV Centers for Disease 127 
Control and Prevention (CDC) clinical stage before TB diagnosis, clinical site of TB disease, TB diagnostic 128 
tests, including radiology, drug susceptibility testing, laboratory tests (CD4 count and percentage, VL, 129 
liver function tests), treatment, and TB outcomes. Data collection started in April 2013, with final follow-130 
up in December 2015. Individual cohorts followed their local ethics approval procedures for 131 
collaborative observational studies. 132 
 133 
 134 
Definitions 135 
TB was categorised as confirmed or clinically diagnosed.15 Confirmed cases were verified by isolation of 136 
Mycobacterium tuberculosis complex using culture and/or molecular tests or identification of acid-fast 137 
bacilli by microscopy in the absence of positive cultures for non-tuberculous mycobacteria. 138 
Immunological evidence of M.tuberculosis infection included positive tuberculin skin test (TST) and/or 139 
interferon-gamma release assays (IGRA). Clinical forms of TB were categorised into pulmonary, extra-140 
pulmonary, and both pulmonary and extrapulmonary; TB disease was classified as severe and non-141 
severe.16 We adapted the consensus adult TB-immune reconstitution inflammatory syndrome (IRIS) case 142 
definition for paediatric use.17 TB-IRIS was defined as a new TB diagnosis or worsening of TB without 143 
alternative explanation following initiation, reintroduction or change in ART and evidence of either (1) a 144 
more than two-fold rise in CD4 count, (2) a reduction in VL of >0.5 log10, or (3) weight gain or other signs 145 
of clinical improvement in response to ART. ATT outcomes were classified as cured, treatment 146 
completed, treatment not completed, TB recurrence, TB-related death, TB-unrelated death, and 147 
outcome not known. Time of viral suppression was defined at the midpoint of the first VL≤400 copies/ml 148 
and the preceding measurement. Height-for-age and body mass index (BMI) Z-scores were used to 149 
assess stunting and wasting, respectively.18 150 
 151 
Statistical analysis 152 
5 
 
TB incidence per 100,000 PY was calculated as the reported number of incident TB cases in the 153 
participating cohorts in the three year study period divided by the number of children at risk (estimated 154 
as 3*number of children under follow-up at the end of 2013). Characteristics of children were compared 155 
according to TB outcome using Fisher’s exact test for categorical variables and Wilcoxon’s rank-sum test 156 
for continuous variables. Adjusted analysis was not possible due to the small sample size. Statistical 157 
analyses were conducted in Stata v14.0 (Stata Corp, College Station, TX, USA). 158 
 159 
 160 
  161 
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RESULTS  162 
Of 4,265 children aged <16 years under follow-up, 127 (3%) were diagnosed with TB between 2011 and 163 
2013. The proportions of children with TB were respectively 1%, 3%, 5% and 8% for participating cohorts 164 
in Western Europe, Eastern Europe, Thailand and Brazil; the estimated TB incidence rates were 165 
respectively 239, 982, 1633 and 2551/100,000 PY. 166 
 167 
Sociodemographic characteristics and anthropometry at TB diagnosis are presented in Table 1. The 168 
median age at diagnosis was 6.8 years, with 51 (40%) aged <5 years. Children in Eastern Europe were 169 
significantly younger than those elsewhere (p=0.0050, comparing median age). Of 119 children with 170 
available data, 115 were residing in their country of origin. 171 
 172 
HIV characteristics and ART at the time of TB diagnosis are presented in Table 2. The majority of the 173 
children had been infected perinatally (94%) and were diagnosed with TB after HIV (80%). In Thailand 174 
children were more immunocompromised than in other regions (p<0.0001, comparing none/mild and 175 
advanced/severe immunological stage); and in Brazil, more children had a CDC stage C event before TB 176 
diagnosis than elsewhere (p=0.0003). Of those children not on ART at TB diagnosis (n=67), 93% 177 
initiated/restarted ART at a median 1.8 months (interquartile range [IQR] 0.8-3.9). Children who 178 
developed TB on ART (n=60) had their TB diagnosis at a median 29.7 months (IQR 6.1-55.0) after ART 179 
initiation, and 51% (23/45) of those with available results had VL ≤400 copies/ml. Five patients had 180 
conventional substitutions to avoid or minimise drug interactions with rifampicin (RMP) following TB 181 
diagnosis; 12 had a change of ART due to toxicity and 23 for treatment failure during ATT. Of the 51 ART-182 
naïve children who started ART while on ATT and had measurements available, 48 (94%) achieved VL 183 
≤400 copies/ml in the first 12 months. Of those on ART at TB diagnosis with measurements available, 184 
3/21 were not virologically suppressed at the end of ATT and after 12 months on ART. 185 
  186 
TB characteristics are presented in Table 3. Overall, 59 (46%) children had a history of TB contact. Eight 187 
children had a history of previous TB, of whom 2 were cured, 5 completed treatment and 1 had an 188 
unknown outcome; 3 children had completed treatment for previous TB within 2 years of the current 189 
episode, suggesting possible relapse. The use of preventative ATT was reported in 23% (n=23) of the 102 190 
children who were diagnosed with HIV before TB: 18 received isoniazid (INH) preventive treatment (IPT), 191 
4 received INH and pyrazinamide, and 1 received INH and ethambutol (EMB). 192 
 193 
Overall, 97 (76%) children had mycobacterial culture and/or molecular tests sent; 35 (28%) were 194 
confirmed cases based on culture or polymerase chain reaction, increasing to 48 (38%) confirmed based 195 
on any test; the proportion with confirmed TB was lowest in Thailand (Table 3). Of the 111 (87%) 196 
children with immunological tests for tuberculous infection, 4 underwent IGRA, 101 underwent TST and 197 
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6 underwent both IGRA and TST. Of those tested 46 (41%) had evidence of tuberculous infection based 198 
on positive IGRA or TST >5 mm.  199 
 200 
Of 23 children who underwent drug susceptibility resistance testing, five (4 in Eastern Europe, 1 in 201 
Western Europe) had drug-resistant M.tuberculosis: 1 had resistance to INH, 1 to INH plus EMB, 3 had 202 
multidrug-resistant TB (MDR-TB, defined as resistance to at least INH and RMP) (2 with resistance to INH 203 
and RMP, and 1 with resistance to INH, RMP, EMB, streptomycin [SM], kanamycin and capreomycin, i.e. 204 
pre-extensively drug-resistant TB). A further four children in Eastern Europe had presumed MDR-TB 205 
based on the DST pattern of the source case.  206 
 207 
Most (89%) children were symptomatic at presentation, with cough, fever and weight loss in 208 
respectively 61%, 54% and 30%; 17% (n=18) of the 104 children had symptoms for >3 months. The most 209 
common clinical presentation was pulmonary TB alone, and overall one-third of children had severe 210 
forms of TB. There were no geographic differences in the proportion with severe TB (p=0.4091) and no 211 
age differences in children with severe and non-severe TB (median age for severe and non-severe TB 7.4 212 
years, IQR 3.0-13.1 and 6.4, IQR 3.4-10.7, respectively; p=0.4241). TB-IRIS was reported in seven cases at 213 
a median of 2.3 months after ART initiation (IQR 1.1-8.8); all had newly diagnosed TB.     214 
 215 
Details of ATT are presented in Table 4. In 118 children treated for suspected drug-susceptible TB, 90% 216 
started rifamycin-based treatment, with 9% receiving rifabutin and 2% rifapentin (RPT). Overall, SM was 217 
used in 25 (20%) children; almost all (n=24) were from Eastern Europe, including 21 children who had TB 218 
for the first time.  The use of less than three second-line ATT drugs in the initial regimen without 219 
documented or suspected TB resistance was reported in one fifth of treated children, most frequently in 220 
Eastern Europe  (p=0.0093). The overall median duration of ATT among those with drug-susceptible TB 221 
was 9.5 months (IQR 7.8-12.4); children in Brazil received the shortest treatment (p=0.0013). ATT was 222 
generally well tolerated, with only one child experiencing a grade 3 alanine transaminase/aspartate 223 
transaminase elevation. 224 
  225 
Eleven (9%) children had unfavourable ATT outcomes. Two children died during initial ATT; both were 226 
severely immunocompromised; one died 2 weeks and the other 4 months after TB diagnosis, the latter 227 
had TB-IRIS.  Five children interrupted ATT and did not complete it, and one was transferred out with no 228 
data on TB outcome. Of the children remaining in follow-up, two had TB recurrence, of whom one 229 
subsequently died from a systemic infection. One additional child from Eastern Europe died of non-TB 230 
related cause (severe HIV encephalopathy) 18 months after completing ATT. None of children with 231 
unfavourable outcomes had suspected or confirmed TB resistance.  232 
 233 
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In unadjusted analysis (Table 5), children from Brazil, those not virologically suppressed on ART and 234 
those with a previous CDC stage C event had a significantly increased probability of an unfavourable TB 235 
outcome. Although a greater proportion of children with an unfavourable outcome had 236 
advanced/severe World Health Organization (WHO) stage at TB diagnosis, this was not statistically 237 
significant.  238 
 239 
 240 
 241 
 242 
  243 
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DISCUSSION 244 
In this study we evaluated TB in HIV-infected children followed in cohorts/clinical sites in high- and 245 
middle-income countries. Estimated TB incidence rates indicate that incident TB in this population is 246 
substantially higher than in the general population in the same countries.1,19,20 The younger age of the 247 
TB cases in Eastern Europe may reflect the more recent HIV epidemic there. Children with TB living in 248 
Thailand or Brazil tended to have more severe HIV disease than those in Europe at TB diagnosis, possibly 249 
due to suboptimal access to care for populations most-at-risk of HIV and TB.  250 
For most TB cases in our study, the HIV diagnosis came first. IPT in known HIV-infected children was 251 
underutilised (reported in only 23% children), and represents a missed opportunity for TB prevention. 252 
IPT was effective in preventing TB in HIV-infected children in sub-Saharan Africa,3,21,22 and is also an 253 
effective adjunct to early ART for TB prevention in adults23, however, its role in unexposed children has 254 
been debated.3,24 The WHO recommends 6 months of post-exposure IPT for all HIV-infected children 255 
and pre-exposure IPT for children aged >1 year26, although IPT implementation has been unacceptably 256 
slow in most countries.1 Increased pill burden, perceived negative effect on ART adherence, exaggerated 257 
fear of developing resistance, poor integration between vertical HIV and TB systems, and insufficient 258 
training among health professionals may be barriers for implementation that need to be addressed. A 259 
recently developed fixed-dose formulation of INH, co-trimoxazole and B6 26 may improve coverage 260 
among older children. Other simplified approaches, such as preventive treatment with once weekly RPT 261 
and INH are promising 27 and need further study in HIV-infected children on ART. In the settings with 262 
high INH resistance, such as Eastern Europe,28 the efficacy of IPT and other preventive treatment 263 
regimens needs further evaluation.  264 
 265 
Two-thirds of study cases had clinically diagnosed TB, similar to other paediatric TB studies.29 This 266 
underscores the importance of initiating ATT without laboratory confirmation in the presence of 267 
symptoms suggestive of TB and the need for better diagnostics. Unlike natural history studies which 268 
showed young children have higher risk of severe TB disease,30 we found no age difference in severe and 269 
non-severe disease, possibly because HIV-related immunodeficiency progresses with age in untreated 270 
children and ART does not fully restore immune function.   In line with other studies from high TB and 271 
HIV burden countries,2,3,31 we showed a high proportion of severe forms of TB (39%) including severe 272 
extrapulmonary TB (27%). In contrast, studies in general paediatric populations reported severe 273 
extrapulmonary forms only in 10-15% of all cases.32,33  274 
 275 
Our study highlights different management practices in paediatric TB across the regions, including more 276 
SM use and suboptimal use of second-line drugs in Eastern Europe. SM is injected intramuscularly due 277 
to poor oral absorption, has high toxicity and limited additional efficacy when added to first-line TB 278 
treatment and is therefore not recommended.34 Use of less than three second-line drugs in high MDR-TB 279 
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burden settings also raises concern as it provides suboptimal activity of the empiric ATT regimen35 and  280 
may propagate further resistance. Such practices should be discouraged and addressed through training 281 
of paediatric TB and HIV clinicians in the region, expanding international collaboration, audits and 282 
studies on implementation of the WHO guidelines, and stewardship of anti-tuberculous drugs. 283 
Government commitment to allocate sufficient budget and dedicated personnel for the monitoring and 284 
evaluation of collaborative TB-HIV activities is necessary for the successful implementation of WHO 285 
guidance. 286 
 287 
RMP has significant drug interactions with protease inhibitors (PIs) and nevirapine. RMP-based ATT was 288 
associated with virological failure and resistance in children on PI-based ART.12,14  Good HIV outcomes 289 
were previously reported for efavirenz (EFV) based ART.13,35 Although only a quarter of our cases 290 
received EFV-based ART, the overall rate of virologically non-suppressed children was less than 10%. 291 
Favourable outcomes were achieved in 92% of children, slightly higher than the 69-88% reported 292 
elsewhere.2,10,11 Previous acquired immune-deficiency syndrome (AIDS) diagnosis, not being virologically 293 
supressed at TB diagnosis, and region (Brazil) were associated with unfavourable TB outcomes.  294 
However as small numbers precluded adjusted analyses, these results should be interpreted with 295 
caution as they are subject to confounding (e.g. children from Brazil were older and were more likely to 296 
have a previous AIDS diagnosis than other children). The proportion of TB-related deaths (1.6%) is 297 
relatively low compared to 3.3-11.7% in the literature.2,4,7,10,11 This may reflect the health status of our 298 
cases with nearly half had no/mild immunodeficiency and less than a third had AIDS.  299 
 300 
This study has a number of limitations, including an observational design, with inherent limitations such 301 
as incomplete data and possible underreporting of cases. However, we distributed reminders to report 302 
all children with suspected TB regardless of follow-up status. Over-diagnosis of TB was possible as most 303 
of our cases were presumptive. Our incidence rates were estimated based on cohort/clinic size, and 304 
should be interpreted with caution. Finally, as we did not have national coverage in each country, except 305 
for the United Kingdom, the results may not be generalizable to the whole country as differences in HIV 306 
and TB epidemiology and healthcare provision likely exist.  307 
 308 
CONCLUSION 309 
TB incidence appears to be higher in HIV-infected children than in the general population from the same 310 
countries. Intensifying use of preventive treatment in the studied cohorts and universal ART initiation in 311 
all HIV-infected children would reduce missed opportunities to prevent TB in HIV-infected children. 312 
Some prescribing practices in Eastern Europe are sub-optimal and should be addressed. Despite 313 
differences in management, most children had good outcomes.  314 
 315 
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Table 1 Socio-demographic characteristics and anthropometry at TB diagnosis 459 
 460 
  461 
 Western Europe 
(N=6) 
Eastern Europe 
(N=80) 
Thailand  
(N=27) 
Brazil 
(N=14) 
Overall 
(N=127) 
 n (%) or median (interquartile range, IQR) 
Male 2 (33) 33 (41) 14 (52) 6 (43) 55 (43) 
Age (years) 10.9 (2.3, 14.0) 5.3 (3.0, 9.4) 7.9 (4.3, 12.6) 14.2 (3.5, 15.0) 6.8 (3.0, 11.5) 
Age (years) 
   <5 years 2 (33) 38 (48) 7 (26) 4 (29) 51 (40) 
   5-10 years 0 25 (31) 9 (33) 2 (14) 36 (28) 
   >10 years 4 (67) 17 (21) 11 (41) 8 (57) 40 (32) 
Ethnicity 
   White 0 61 (76) 0 5 (36) 66 (52) 
   Asian 0 0 27 (100) 0 27 (21) 
   Hispanic 0 0 0 4 (29) 4 (3) 
   Black 6 (100) 1 (1) 0 3 (21) 10 (8) 
   Other 0 18 (23) 0 0 18 (14) 
   Unknown 0 0 0 2 (14) 2 (2) 
Height-for-age z-score <-2  
(n=3, 66, 26, 6, 101) 
0 22 (33) 20 (77) 2 (33) 44 (44) 
BMI-for-age z-score <-2  
(n=3, 66, 26, 5, 100) 
0 8 (12) 7 (27) 2 (40) 17 (17) 
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Table 2 HIV characteristics at TB diagnosis 462 
 463 
*Including 15 children diagnosed with HIV after TB, and 3 children who had previously initiated ART but were off 464 
ART at TB diagnosis.  465 
§ Including five children who initiated ART after completing ATT.  466 
†Defined as switching from boosted PI to EFV-based/3 NRTI regimen, or addition of RTV to existing PI in period 7 467 
days before or during anti-TB treatment.  468 
^Of 27 children aged <3 years on ART, 14 received PI-based regimens, 7 NNRTI-based, and the rest had other 469 
regimens. 470 
ART=antiretroviral therapy. ATT=anti-tuberculosis treatment. CDC=Centers for Disease Control and Prevention. 471 
MTCT=mother-to-child transmission. PI=protease inhibitors. NRTI=nucleoside/nucleotide reverse transcriptase 472 
inhibitors. VL=viral load 473 
 474 
 475 
 476 
 477 
 Western Europe 
(N=6) 
Eastern Europe 
(N=80) 
Thailand  
(N=27) 
Brazil 
(N=14) 
Overall 
(N=127) 
 n (%) or median (interquartile range, IQR) 
Mode of HIV infection 
   Perinatal infection 5 (83) 77 (96) 25 (93) 12 (86) 119 (94) 
   Blood transfusion 1 (17) 0 0 0 1 (1) 
   Unknown 0 3 (4) 2 (7) 2 (14) 7 (6) 
Age at HIV diagnosis (years) 6.8 (1.2, 13.9) 1.3 (0.2, 5.1) 7.2 (4.2, 10.3) 4.4 (1.4, 8.3) 2.7 (0.5, 7.2) 
Timing of HIV/TB diagnosis  
   Diagnosed with TB & HIV within ±7d 1 (17) 4 (5) 5 (19) 0 10 (8) 
   Diagnosed with TB >7d before HIV 1 (17) 8 (10) 5 (19) 1 (7) 15 (12) 
      Time from TB to HIV (months) 0.7  0.9 (0.5, 1.4) 2.1 (0.5, 11.0) 0.9  0.9 (0.5, 2.1) 
   Diagnosed with TB >7d after HIV 4 (67) 68 (85) 17 (63) 13 (93) 102 (80) 
      Time from HIV to TB (months)  6.5 (1.7, 60.4)  35.2 (11.1, 68.7) 2.1 (1.4, 19.3) 38.7 (16.2, 108.9)  33.4 (6.9, 66.8) 
WHO immunological stage (n=6, 77, 24, 14, 121) 
   None/Mild 5 (83) 44 (57) 3 (13) 6 (43) 58 (48) 
   Advanced/Severe 1 (17) 33 (43) 21 (88) 8 (57) 63 (52) 
CD4% (n=6, 77, 23, 13, 119) 32 (17, 43) 26 (14, 35) 10 (5, 17) 18 (15, 29) 18 (15, 29) 
CD4 count (cells/μL), age ≥5 years (n=4, 
41, 17, 10, 72) 
594 (233, 909) 397 (202, 654) 54 (30, 119) 269 (138, 469) 275 (56, 564) 
Viral load (log10) (n=6, 63, 4, 11, 84) 4.5 (2.0, 4.9) 4.1 (2.2, 5.5) 4.3 (3.3, 5.4)  2.3 (1.7, 4.9) 4.1 (1.9, 5.2)  
CDC clinical stage C prior to TB diagnosis 
(n=6, 69, 27, 14, 116) 
1 (17) 16 (23) 9 (33) 11 (79) 37 (32) 
Off ART/ART naïve at TB diagnosis* 4 (67) 40 (50) 21 (78) 2 (14) 67 (53) 
   Restarted/initiated ART by end of  
   follow up§ 
4 37 20 1 62 
   Time to ART restart/initiation (months) 2.2 (0.6, 4.7) 1.5 (0.8, 3.2) 2.1 (0.9, 4.3) 4.8 1.8 (0.8, 3.9) 
On ART at TB diagnosis 2 (33) 40 (50) 6 (22) 12 (86) 60 (47) 
   Any TB-related ART modification† 0 4 0 1 5 
Summary of ART during ATT^ 
   Boosted PI-based 1 (17) 40 (50) 3 (11) 8 (57) 52 (41) 
   Efavirenz-based 0 17 (21) 13 (48) 3 (21) 33 (26) 
   Nevaripine-based 1 (17) 5 (6) 8 (30) 0 14 (11) 
   3NRTI 0 5 (6) 0 0 5 (4) 
   Other 3 (50) 9 (11) 0 2 (14) 14 (11) 
   No ART while on ATT 1 (17) 4 (5) 3 (11) 1 (7) 9 (7) 
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Table 3  Characteristics of current TB  478 
 479 
 Western 
Europe 
(N=6) 
Eastern 
Europe 
(N=80) 
Thailand  
(N=27) 
Brazil 
(N=14) 
Overall 
(N=127) 
 n (%) 
History of TB contact 3 (50) 44 (55) 11 (41) 1 (7) 59 (46) 
History of previous TB 1 (17) 4 (5) 0 3 (21) 8 (6) 
Case definition  
   Confirmed* 3 (50) 29 (36) 7 (26) 9 (64) 48 (38) 
   Clinically diagnosed 3 (50) 51 (64) 20 (74) 5 (36) 79 (62) 
Clinical presentation 
   Pulmonary only 3 (50) 38 (48) 18 (67) 7 (50) 66 (52) 
   Extrapulmonary only§ 3 (50) 22 (28) 6 (22) 5 (36) 36 (28) 
      Lymph nodes 1 16 5 1 23 
      Spine/bone/joints 1 0 0 0 1 
      Gastro-intestinal 0 2 1 0 3 
      Genito-urinary tract 0 0 0 1 1 
      Miliary 0 8 1 3 12 
      Other 2 1 0 0 3 
   Pulmonary and extrapulmonary§        0 20 (25) 3 (11) 2 (14) 25 (20) 
      Pleura  0 1 0 0 1 
      Lymph nodes 0 14  3 0 17 
      Spine/bone/joints 0 0 0 1 1 
      CNS/meningitis 0 3 0 0 3 
      Gastro-intestinal 0 2 0 0 2 
      Skin 0 0 1 0 1 
      Genito-urinary tract 0 1 0 0 1 
      Other 0 7 0 1 8 
Severe TB 3 (50) 28 (35) 11 (41) 8 (57) 50 (39) 
Any clinical symptoms present 6 (100) 68 (85) 26 (96) 13 (93) 113 (89) 
*Based on culture, molecular tests, microscopy or histology.  480 
§Children may have >1 site of TB summarised. 481 
  482 
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Table 4  TB treatment, toxicity and treatment outcomes 483 
 484 
 Western Europe 
(N=6) 
Eastern Europe 
(N=80) 
Thailand  
(N=27) 
Brazil 
(N=14) 
Overall 
(N=127) 
 n (%) or median (interquartile range, IQR) 
Initial treatment regimen (drug-sensitive TB only) (n=5, 72, 27, 14, 118) 
   Rifamycin included in ATT 5 (100) 62 (86) 25 (93) 14 (100) 106 (90) 
   Rifamycin not included in ATT  0 10 (14) 2 (7) 0 12 (10) 
Streptomycin use  0 24 (30) 1 (4) 0 25 (20) 
Use of ≤3 second-line ATT drugs with 
no confirmed/suspected resistance 
0 20 (25) 4 (15) 0 24 (19) 
Treatment duration of drug-sensitive, 
TB* (months) (n=5, 65, 26, 8, 104) 
 8.9 (6.1, 12.0)  9.6 (8.0, 12.0)  12.2 (8.9, 13.2)  6.6 (6.2, 7.2)  9.5 (7.8, 12.4) 
Any drug discontinued for any toxicity 1 (17) 6 (8) 4 (15) 0 11 (9) 
Any drug discontinued for 
hepatotoxicity 
0 2 (3) 2 (7) 0 4 (3) 
Any elevated ALT/AST on treatment (n=5, 66, 24, 11, 106) 
   Grade 1 (50 to 99 IU/L) 2 (40) 18 (27) 5 (26) 3 (27) 28 (29) 
   Grade 2 (100 to 199 IU/L) 0 6 (9) 4 (17) 0 10 (9) 
   Grade 3 (≥200 IU/L) 0 0 1 (4) 0 1 (1) 
Outcome 
   Cure 1 (17) 41 (51) 3 (11) 5 (36) 50 (39) 
   Treatment completed^ 5 (83) 34 (43) 23 (85) 4 (29) 66 (52) 
   Treatment not completed 0 2 (3) 0 3 (21) 5 (4) 
   Recurrence of TB - survived 0 0 1 (4) 0 1 (1) 
   Died – TB-related 0 2 (3) 0 0 2 (2) 
   Died – not TB-related§ 0 1 (1) 0 1(7) 2(2) 
   Not known 0 0 0 1 (7) 1 (1) 
* Including only participants with completed treatment.  485 
§ One child from Brazil had TB recurrence and died later of non-specified systemic infection– assigned to not TB-486 
related deaths.  487 
^ One child from Thailand interrupted treatment for 5 months after 4 months of treatment, before restarting and 488 
completing treatment – assigned to treatment completed.  489 
ALT=alanine aminotransferase. AST=aspartate aminotransferase. ARV=antiretroviral drugs. ATT=anti-tuberculosis 490 
treatment. MDR-TB=multidrug-resistant tuberculosis.  491 
 492 
  493 
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Table 5  Outcomes of TB 494 
 495 
 Favourable  
Outcome* 
(N=116) 
Unfavourable 
outcome 
(N=11) 
p-value 
 n (%) or median (IQR)  
Age at TB diagnosis 6.7 (3.0, 11.3) 11.1 (5.4, 15.4) 0.1071 
Region 
0.0099 
   Western Europe 6 (100) 0 
   Eastern Europe 75 (94) 5 (6) 
   Thailand 26 (96) 1 (4) 
   Brazil 9 (64) 5 (36) 
Gender 
0.7556    Male 51 (93) 4 (7) 
   Female 65 (90) 7 (10) 
ART/virological suppression status at TB diagnosis  
   ART naïve 64 (100) 0  
   ART experienced 52 (83) 11 (17)  
      VL≤400 22 (96) 1 (4) 
0.0429^ 
      VL>400 16 (70) 7 (30) 
      Unknown VL 14 (82) 3 (18)  
WHO immunological stage at TB diagnosis 
0.0978    None/Mild 56 (97) 2 (3) 
   Advanced/Severe 55 (87) 8 (13) 
CDC stage prior to TB diagnosis 
0.0356    N/A/B 75 (95) 4 (5) 
   C 30 (81) 7 (19) 
Severity of TB 
0.3398    Severe 44 (88) 6 (12) 
   Not severe 72 (94) 5 (6) 
Mode of diagnosis  
0.3296    Confirmed 42 (88) 6 (13) 
   Clinically diagnosed  74 (94) 5 (6) 
TB-IRIS  
0.1129    Yes 5 (71) 2 (29) 
   No 111 (93) 9 (8) 
Any resistance/suspected resistance? 
1.0000    Yes 9 (100) 0 
   No 107 (91) 11 (9) 
*Favourable clinical outcomes are cure and treatment completed.  496 
^Comparison of ART experienced children with VL ≤400 vs VL>400 c/mL. 497 
ART=antiretroviral treatment. CDC=Centers for Disease Control and Prevention. TB-IRIS=TB-associated immune 498 
reconstitution inflammatory syndrome. VL=viral load. 499 
 500 
 501 
 502 
 503 
 504 
 505 
 506 
 507 
 508 
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 529 
Figure 1  Flowchart of TB cases identified within PENTA cohort collaboration and included in the study 530 
 531 
*Twelve European Cohorts and clinical sites (in Belgium, France, Denmark, Germany, Greece, Italy, 532 
Netherlands, Portugal, Sweden, Switzerland, Poland and Romania) did not have TB cases eligible for the 533 
study; cohort in Argentina did not participate for other reasons. 534 
^Cohorts  and clinical sites participated in the study:  CoRISPE (Spain); CHIPS (United Kingdom and 535 
Ireland); Riga East University Hospital (Latvia); Republican Hospital of Infectious Diseases, St Petersburg 536 
City AIDS Centre and Irkutsk AIDS Centre (Russia); Kryvyi Rih, Donetsk, Kyiv, Mariupol, Mykolaiv, Odessa, 537 
Simferopol AIDS Centres (Ukraine); PHPT  (Thailand), Instituto de Infectologia  Emilio Ribas cohort, São 538 
Paolo (Brazil) 539 
N=number of cohorts and clinical sites. n=number of patients.  540 
 541 
 542 
 543 
 544 
 545 
 546 
 547 
 548 
 549 
 550 
 551 
 552 
15 Paediatric HIV cohorts and clinical sites participated in the study: ^  
Western Europe (N=2), Eastern Europe (N=11), Thailand (N=1), Brazil (N=1) 
Case research forms received on 134 patients  
7 excluded 
         5 had TB diagnosis outside period  
         for inclusion  
         1 aged ≥16 years at TB diagnosis 
         1 had alternative diagnosis and   
         TB was  considered unlikely  
127 cases analysed: 
Western Europe (n=6, 5%), Eastern Europe (n=80, 63%), Thailand (n=27, 21%), Brazil (n=14, 11%) 
28 Paediatric HIV cohorts and clinical sites approached*  
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